Skip to content

Hormones and Social Anxiety Disorder Treatment

Effect of Hormones on Response to Exposure Therapy for Social Anxiety Disorder

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02482805
Enrollment
73
Registered
2015-06-26
Start date
2015-07-01
Completion date
2017-04-01
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Social Anxiety Disorder

Brief summary

The purpose of this study is to determine whether power posing (i.e., holding poses associated with dominance and power), compared to submissive posing or rest, prior to exposure therapy for social anxiety disorder: 1) leads to a temporary increase in testosterone levels and/or 2) facilitates exposure therapy outcomes.

Interventions

BEHAVIORALCognitive Behavioral Therapy

Exposure therapy for social anxiety disorder

Sponsors

Jasper A. Smits
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Outpatients between the ages of 18 to 70 years of age with a primary psychiatric diagnosis (designated by the patient as the most important source of current distress) of social anxiety disorder as defined by DSM-5 criteria, with fear of public speaking endorsed as a primary concern. * Willingness and ability to participate in the informed consent process and comply with the requirements of the study protocol.

Exclusion criteria

* Current use of testosterone enhancing products (i.e., gels, creams, or injections) * A lifetime history of bipolar disorder, schizophrenia, psychosis, or delusional disorders; organic brain syndrome, mental retardation or other cognitive dysfunction that could interfere with capacity to engage in therapy; a history of substance or alcohol abuse or dependence (other than nicotine) in the last 6 months. * Entry of patients with other mood or anxiety disorders will be permitted in order to increase accrual of a clinically relevant sample; however in cases where SAD is not judged to be the predominant disorder, participants will not be eligible. * Patients with significant suicidal ideation or who have enacted suicidal behaviors within 6 months prior to intake will be excluded from study participation and referred for appropriate clinical intervention. * Patients using psychotropic medication (e.g., antidepressants, anxiolytics, beta blockers) must be on a stable dose for three weeks prior to initiation of randomized treatment. * Significant personality dysfunction likely to interfere with study participation. * Patients with a current or past history of seizures. * Any concurrent psychotherapy initiated within 3 months of baseline, or ongoing psychotherapy of any duration directed specifically toward treatment of the SAD is excluded. Prohibited psychotherapy includes CBT or psychodynamic therapy focusing on exploring specific, dynamic causes of the phobic symptomatology and providing management skills. General supportive therapy initiated \> 3 months prior is acceptable. * Prior non-response to adequately delivered exposure (i.e., as defined by the patient's report of receiving specific and regular exposure assignments as part of a previous treatment). * Patients with a history of head trauma causing loss of consciousness, seizure or ongoing cognitive impairment. * Subjects with back pain issues or medical conditions that would make it difficult to hold posture manipulations. * Insufficient command of the English language.

Design outcomes

Primary

MeasureTime frameDescription
LSAS-performance SubscaleScores at 1 week post-treatmentLiebowitz Social Anxiety Scale (LSAS)-Performance Subscale at pre- and 1-week post-treatment. The Liebowitz Social Anxiety Scale (LSAS) - Performance Subscale is a subscale of a common measure of social anxiety symptom severity. This subscale consists of only 13 (of the total 24) items related to performance situations. Participants rate both their fear (0 to 3) and avoidance (0 to 3) of these 13 situations, where higher scores indicate worse social anxiety severity. The minimum possible score on this subscale is 0 and the maximum possible score is 78.
Subjective Units of Distress Scale (SUDs)Scores at 1 week post-treatmentPeak (max) SUDS ratings (0 to 100 scale) during treatment exposure and 1 week post-treatment exposure. Peak Subjective Units of Distress Scale (SUDS) is the maximum amount of fear experienced rated on a 0 to 100 point scale, where 0 indicates no anxiety and 100 indicates the maximum level of anxiety.
Salivary Testosterone LevelsBaseline and 20 minutes after posture manipulationSaliva sample taken before posture manipulation and 20 minutes after. Outcome is the change from pre- to post-manipulation in testosterone levels.

Countries

United States

Participant flow

Participants by arm

ArmCount
Power Posing
Individuals hold two, 1-minute postures associated with dominance and high power prior to exposure therapy. Cognitive Behavioral Therapy: Exposure therapy for social anxiety disorder
26
Submissive Posing
Individuals hold two, 1-minute postures associated with submissiveness and low power prior to exposure therapy. Cognitive Behavioral Therapy: Exposure therapy for social anxiety disorder
27
Rest
Individuals rest (no postures) for 2 minutes prior to exposure therapy. Cognitive Behavioral Therapy: Exposure therapy for social anxiety disorder
20
Total73

Baseline characteristics

CharacteristicPower PosingSubmissive PosingRestTotal
Age, Continuous26.88 years
STANDARD_DEVIATION 6.99
25.26 years
STANDARD_DEVIATION 8.99
24.60 years
STANDARD_DEVIATION 5.83
25.66 years
STANDARD_DEVIATION 7.48
Ethnicity (NIH/OMB)
Hispanic or Latino
5 Participants9 Participants3 Participants17 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
20 Participants17 Participants16 Participants53 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants1 Participants1 Participants3 Participants
LSAS-performance37.96 units on a scale
STANDARD_DEVIATION 14.39
36.19 units on a scale
STANDARD_DEVIATION 10.92
37.85 units on a scale
STANDARD_DEVIATION 10.16
37.27 units on a scale
STANDARD_DEVIATION 11.96
Peak SUDS during exposure76.31 units on a scale
STANDARD_DEVIATION 14.86
77.74 units on a scale
STANDARD_DEVIATION 15.03
77.50 units on a scale
STANDARD_DEVIATION 11.2
77.16 units on a scale
STANDARD_DEVIATION 13.85
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
6 Participants5 Participants3 Participants14 Participants
Race (NIH/OMB)
Black or African American
2 Participants2 Participants3 Participants7 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
4 Participants6 Participants3 Participants13 Participants
Race (NIH/OMB)
White
14 Participants14 Participants11 Participants39 Participants
Region of Enrollment
United States
26 Participants27 Participants20 Participants73 Participants
Sex: Female, Male
Female
18 Participants18 Participants16 Participants52 Participants
Sex: Female, Male
Male
8 Participants9 Participants4 Participants21 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
other
Total, other adverse events
0 / 260 / 270 / 20
serious
Total, serious adverse events
0 / 260 / 270 / 20

Outcome results

Primary

LSAS-performance Subscale

Liebowitz Social Anxiety Scale (LSAS)-Performance Subscale at pre- and 1-week post-treatment. The Liebowitz Social Anxiety Scale (LSAS) - Performance Subscale is a subscale of a common measure of social anxiety symptom severity. This subscale consists of only 13 (of the total 24) items related to performance situations. Participants rate both their fear (0 to 3) and avoidance (0 to 3) of these 13 situations, where higher scores indicate worse social anxiety severity. The minimum possible score on this subscale is 0 and the maximum possible score is 78.

Time frame: Scores at 1 week post-treatment

Population: 4 individuals did not complete LSAS at post-treatment; accordingly the analyses were conducted with only 69 individuals (versus the total sample size of 73) who had complete data.

ArmMeasureValue (MEAN)Dispersion
Power PosingLSAS-performance Subscale34.04 units on a scaleStandard Deviation 14.76
Submissive PosingLSAS-performance Subscale32.54 units on a scaleStandard Deviation 8.74
RestLSAS-performance Subscale32.05 units on a scaleStandard Deviation 13.7
Primary

Salivary Testosterone Levels

Saliva sample taken before posture manipulation and 20 minutes after. Outcome is the change from pre- to post-manipulation in testosterone levels.

Time frame: Baseline and 20 minutes after posture manipulation

ArmMeasureValue (MEAN)Dispersion
Power PosingSalivary Testosterone Levels-2.31 pg/mLStandard Deviation 10.82
Submissive PosingSalivary Testosterone Levels-0.88 pg/mLStandard Deviation 33.31
RestSalivary Testosterone Levels-1.47 pg/mLStandard Deviation 54.56
Primary

Subjective Units of Distress Scale (SUDs)

Peak (max) SUDS ratings (0 to 100 scale) during treatment exposure and 1 week post-treatment exposure. Peak Subjective Units of Distress Scale (SUDS) is the maximum amount of fear experienced rated on a 0 to 100 point scale, where 0 indicates no anxiety and 100 indicates the maximum level of anxiety.

Time frame: Scores at 1 week post-treatment

Population: 8 individuals did not complete the post-treatment exposure; accordingly the analyses were conducted with only 66 individuals (versus the total sample size of 73) who had complete data.

ArmMeasureValue (MEAN)Dispersion
Power PosingSubjective Units of Distress Scale (SUDs)59.26 units on a scaleStandard Deviation 14.43
Submissive PosingSubjective Units of Distress Scale (SUDs)59.17 units on a scaleStandard Deviation 23.85
RestSubjective Units of Distress Scale (SUDs)48.75 units on a scaleStandard Deviation 19.79

Source: ClinicalTrials.gov · Data processed: Jun 16, 2026